{"filings":[{"id":861278,"accession_number":"0001193125-26-257417","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-06-04T20:14:44+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CV Sciences shareholders reject reverse stock split; three directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 2 (reverse stock split up to 1-for-800) failed: 48.5M for, 59.6M against, 8.1M abstain.","Directors elected: Dr. Jamie Corroon (39.5M for), Joseph Dowling (37.7M for), Bill McCorkle (22.7M for, 17.2M abstain).","Ratification of Haskell & White as auditor passed with 102.4M for vs 12.5M against.","Quorum of 60.1% achieved with 116.2M shares represented at the virtual annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442478,"accession_number":"0001193125-26-223967","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-05-14T20:04:49+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.","Gross margin improved to 48.9% (from 46.0% YoY); operating loss $0.3M vs prior year operating income due to $0.5M payroll tax reversal.","Adjusted EBITDA loss of $0.1M vs $0.3M loss in Q1 2025; cash balance $0.3M at quarter end.","Completed debt restructuring to strengthen financial position; launched EMPOWR plant-based protein/creatine formula.","New products launched since Jan 2023 contributed 43% of Q1 net revenue; 45 new products introduced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93296,"accession_number":"0001193125-26-151228","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CV Sciences issues $99,614 senior secured convertible note; conversion price cut to $0.03","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $99,614.04 senior secured convertible note due July 6, 2027 to an institutional investor.","April 9, 2026 amendment reduced fixed conversion price on prior notes from $0.06 to $0.03 per share.","Third Note conversion price fixed at $0.03 (lesser of $0.03 and prior-day closing price of $0.04).","No interest accrues unless Event of Default; then 18% late fee per annum applies.","Conversion subject to 4.99% beneficial ownership limitation (can be increased to 9.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104794,"accession_number":"0001193125-26-126211","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.","Gross margin improved to 49.0% from 45.6%; operating loss reduced to $0.5M from $2.2M.","Adjusted EBITDA loss was $0.3M, improved from $0.8M in 2024; Q4 2025 delivered positive adjusted EBITDA of $0.1M.","Cash balance $0.3M at year-end; completed debt restructuring in Q1 2026 to strengthen financial position.","Launched 39 new products since Jan 2023; new products contributed 39% of FY2025 net revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104793,"accession_number":"0001193125-26-100436","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.","Added conversion feature at $0.06/share, initially convertible into 37.6M shares of common stock.","True-up provision requires additional note if net proceeds from conversion sales fall short of principal.","Company paid $15,000 documentation fee; beneficial ownership cap set at 4.99% (can be raised to 9.99%).","Management says restructuring strengthens balance sheet and positions for sustained profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121077,"accession_number":"0001193125-25-280116","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.","Gross margin 48.5% (Q3 2024: 46.0%; Q2 2025: 50.9%); adjusted EBITDA loss $118K vs $75K loss in Q3 2024.","Cash balance $0.4M at quarter-end; launched +PlusCBD Ignite men's formula. Federal hemp language enacted with one-year delay."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":10482000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121076,"accession_number":"0001193125-25-237188","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences issues $600K secured note with $300K net proceeds; potential add'l $750K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600K secured promissory note with 25% OID ($150K) plus $150K modification fee; net proceeds $300K.","Note matures April 6, 2027; monthly principal payments of $46,153.85 begin April 6, 2026.","Note secured by all company assets and IP; customary default provisions with 18% default interest.","Potential additional $750K note upon consummation of Extract Labs acquisition on terms satisfactory to investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137698,"accession_number":"0001193125-25-207436","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences amends $1.6M secured note, extends maturity to 2027, defers payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original $1.6M note issued Feb 2025 with $400K OID; outstanding balance $1.28M after $320K payments.","New maturity date extended to Feb 12, 2027; monthly redemption schedule modified to defer six months.","First 3 months: $106.7K each; next 6 months: $0; subsequent 12 months: $106.7K each plus accrued interest.","Investor receives $150K cash as consideration; agreement contemplates potential additional $450K secured note.","Company paid $10K investor legal fees at origination; amendment includes cash payment of $150K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137697,"accession_number":"0000950170-25-107984","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.","Gross margin 50.9%, highest since Q3 2019, up from 47.0% in Q2 2024.","Adjusted EBITDA positive $0.1M, first since Q2 2019, vs -$6k in Q2 2024.","Cash balance $0.9M at quarter end, up from $0.5M at end of 2024.","CEO cites state regulatory pressure for sales decline; pushing M&A and new products."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":7226000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155083,"accession_number":"0000950170-25-081934","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CV Sciences annual meeting: directors elected, auditor ratified, say-on-pay approved at 2-year frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 54.6% (100.7M of 184.3M shares); directors Corroon, Dowling, McCorkle elected with 17.0M-32.9M votes for.","Haskell & White LLP ratified as auditor for FY2025: 92.5M for, 6.9M against, 1.3M abstain.","Non-binding advisory vote on executive compensation approved: 28.6M for, 5.4M against, 2.0M abstain.","Advisory vote on frequency: Every 2 years approved (27.4M votes), 1 year (5.1M), 3 years (2.0M), abstain (1.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155082,"accession_number":"0000950170-25-071347","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 2025 revenue $3.6M (-10% YoY); turns operating profit $11K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.6M vs $4.0M YoY; unit volume down 11.8%, partially offset by 0.9% price increase.","Operating income of $11K vs $0.6M loss YoY, boosted by $0.5M reversal of accrued payroll taxes.","Adjusted EBITDA loss improved to $0.3M from $0.5M YoY; gross margin 46.0% vs 46.3%.","Launched Lunar Fox plant-based product line with 7 vegan products in U.S. retail and online.","Raised $1.2M net from institutional investor in Q1; cash balance $0.8M vs $0.5M end-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3606000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173602,"accession_number":"0000950170-25-045761","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).","Gross margin improved to 45.6% from 44.3%; adjusted EBITDA loss narrowed to $0.8M from $2.3M.","Cash balance $0.5M at year-end vs $1.3M; net proceeds of $0.9M from Streeterville financing in Q3 2024.","Acquired Elevated Softgels in Q2 2024; launched +PlusHLTH brand and Lunar Fox plant-based line.","Retained Maxim Group as non-exclusive financial advisor; evaluating M&A opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173601,"accession_number":"0000950170-25-023618","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences issues $1.6M secured promissory note, net proceeds $1.2M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $1.6M with $400K original issue discount, net $1.2M to company.","Monthly payments of $106,666.67 begin June 12, 2025; maturity August 12, 2026.","Note secured by all company assets and intellectual property; interest only accrues on default.","Early repayment in full by August 13, 2025 qualifies for $100K discount.","Proceeds used to pay off existing Streeterville Capital debt and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173600,"accession_number":"0000950170-25-022630","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CV Sciences initiates arbitration against former legal counsel Procopio over faulty RSU tax advice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitration filed Feb 12, 2025; claims Procopio provided incorrect tax advice on CEO Mona's RSU settlement.","Shares valued >$13M were issued to Mona without tax withholding based on Procopio's guidance.","Procopio later reversed its advice and terminated representation on Jan 10, 2025.","Company seeks damages including fees and expenses from reliance on the faulty advice.","Lack of withholding has been disclosed in SEC filings since Q1 2019 and led to prior litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173599,"accession_number":"0000950170-25-018048","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["1.02","1.01"],"status":"ready","headline":"CV Sciences disputes Extract Labs acquisition termination by Sellers; evaluating options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Feb 5, 2025, Extract Labs owners informed CV Sciences they cannot close due to alleged failure to obtain bank consent, purportedly terminating the Stock Purchase Agreement.","CV Sciences disputes the Sellers' right to terminate and reserves all rights; evaluating legal options.","The Purchase Agreement was entered on Nov 21, 2024, for CV Sciences to acquire all outstanding shares of Extract Labs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190578,"accession_number":"0000950170-24-130576","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CV Sciences prevails in arbitration against former executive Michael Mona Jr.","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On Nov 20, 2024, arbitrator ruled in favor of CV Sciences and management, denying all claims by Mona.","Mona had sought recovery of taxes, interest, and penalties from RSU vesting in 2019, alleging breach of contract.","Arbitration began April 8, 2024, concluded May 23, 2024; award received Nov 20, 2024.","Case originated from a Nevada state court complaint filed Nov 5, 2021, later ordered to arbitration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190577,"accession_number":"0000950170-24-129750","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.","Earnout tied to Extract Labs revenue targets: $3.5M-$4.6M per 12-month period for two years.","Acquisition expected to close in Q1 2025, subject to customary conditions.","CV Sciences plans to in-source +PlusCBD production, citing cost savings and supply chain control.","Extract Labs described as stand-alone profitable, GMP-certified, and FDA-registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190576,"accession_number":"0000950170-24-126787","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.","Gross margin improved to 46.0% from 45.1% YoY; operating loss narrowed to $0.3M from $0.4M.","Adjusted EBITDA loss of $75k, near breakeven versus $0.4M loss a year ago.","Cash balance $1.0M at quarter end; secured $0.9M net proceeds from Streeterville financing.","Launched +PlusHLTH supplement line (CLARITY, PEACE, RESHAPE) and new pet chews."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":11821000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207073,"accession_number":"0000950170-24-095801","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 2024 revenue flat at $4.0M; gross margin improves to 47%, adjusted EBITDA near breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.","Gross margin 47.0% vs 43.3% YoY, best in 13 quarters; operating loss narrowed to $0.6M from $1.1M.","Adjusted EBITDA loss just $6,000, near cash-flow breakeven; cash balance $0.5M vs $1.3M year-end 2023.","Closed acquisition of Elevated Softgels in May 2024; appointed Maxim Group as financial advisor for strategic options.","Received net proceeds of $0.9M from Streeterville financing; remains top hemp extract brand per SPINS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7956000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207072,"accession_number":"0000950170-24-082225","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences enters $1.19M secured note with Streeterville Capital, net proceeds $900K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $1,188,500; net proceeds $900,000 after $283,500 OID and $5,000 fees.","Weekly repayments of $22,855.77; maturity 12 months from July 3, 2024.","Note secured by all assets; default interest 22% per annum on event of default.","Early repayment discount of $75,000 if paid in full by Dec 31, 2024.","Guaranties from subsidiaries: Star Sky Foods, Cultured Foods Sp. z o.o., Elevated Softgels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224394,"accession_number":"0000950170-24-076955","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CV Sciences enters new 3-year employment agreements with CEO and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Joseph Dowling new base salary $300K/year, target annual bonus 50% of base.","CFO Joerg Grasser new base salary $235K/year, target annual bonus 20% of base.","Both agreements run through June 20, 2027, with change-of-control severance of 2x base salary.","Dowling has $433,871 in deferred base salary plus $490,274 total accrued (2020-2022).","Dowling eligible for $1,500/month car allowance and $1.5M life insurance paid by company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224393,"accession_number":"0000950170-24-069998","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CV Sciences stockholders elect directors, ratify auditor, approve exec comp at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 53.1% achieved with 86,682,380 shares represented at June 3, 2024 meeting.","Three directors elected: Dr. Jamie Corroon (28,999,412 for), Joseph Dowling (26,074,685 for), Bill McCorkle (28,764,821 for).","Ratification of Haskell & White LLP as auditor for FY2024 passed with 84,248,548 for, 1,837,030 against.","Non-binding advisory vote on named executive officer compensation approved with 20,844,946 for, 9,562,945 against.","All proposals passed with broker non-votes on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224392,"accession_number":"0000950170-24-059152","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.","Gross margin 46.3%, best in 12 quarters, up from 43.0% in Q1 2023.","Operating loss $0.6M vs operating income $5.8M in Q1 2023 (due to reversal of accrued payroll tax of $6.2M).","Adjusted EBITDA negative $0.5M vs negative $0.2M in Q1 2023; cash $0.7M down from $1.3M.","Acquired Elevated Softgels, a Colorado softgel and tincture manufacturer; no deal terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":4002000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224391,"accession_number":"0000950170-24-058981","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.","Elevated Softgels is a GMP-certified, FDA-registered manufacturer of softgels and tinctures.","CEO says acquisition expected to be accretive in first year; softgels and tinctures were ~50% of 2023 sales.","Plans to in-source manufacturing of +PlusCBD branded products for meaningful cost savings.","Earnout thresholds: $200k if net revenue ≥$700k in 12 months, $0 if <$550k, with intermediate steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243707,"accession_number":"0000950170-24-037652","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2023 revenue $16.0M (flat), gross margin improves to 44.3% from 34.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.0M for FY2023, flat vs $16.2M in 2022; Q4 revenue $3.8M down 2% YoY.","Gross margin 44.3% (FY2022: 34.2%); operating income $3.4M vs loss $6.8M, helped by $6.2M payroll tax reversal.","Cash $1.3M at year-end; cash from operations $2.3M including $2.5M employee retention credit.","Adjusted EBITDA negative $2.3M in FY2023, improved from negative $6.1M in FY2022.","Acquired Cultured Foods in Q4 2023; launched new products; #1 hemp extract brand in natural retail per SPINS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}